PE20191546A1 - Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb - Google Patents
Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bbInfo
- Publication number
- PE20191546A1 PE20191546A1 PE2019001290A PE2019001290A PE20191546A1 PE 20191546 A1 PE20191546 A1 PE 20191546A1 PE 2019001290 A PE2019001290 A PE 2019001290A PE 2019001290 A PE2019001290 A PE 2019001290A PE 20191546 A1 PE20191546 A1 PE 20191546A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- binding
- antigen
- domain
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 6
- 102000036639 antigens Human genes 0.000 title abstract 6
- 108091007433 antigens Proteins 0.000 title abstract 6
- 210000004027 cell Anatomy 0.000 abstract 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 abstract 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Multimedia (AREA)
- Signal Processing (AREA)
- Physics & Mathematics (AREA)
- Computer Hardware Design (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
Abstract
Referido a una molecula de union a antigeno biespecifica, que comprende al menos un dominio de union al antigeno capaz de unirse de manera especifica a 4-1BB, al menos un dominio de union al antigeno capaz de unirse a un antigeno de celula diana y un dominio Fc. Dicho dominio de union a 4-1BB, comprende una region variable de la cadena pesada, que comprende (i) CDR-H1 de SEQ ID NO: 1, (ii) CDR-H2 de SEQ ID NO: 2 y (iii) CDR-H3 de SEQ ID NO: 3; y una region variable de cadena ligera, que comprende (iv) CDR-L1 de SEQ ID NO: 4, (v) CDR -L2 de SEQ ID NO: 5, y (vi) CDR-L3 de SEQ ID NO: 6. El antigeno de celula diana se selecciona entre la proteina de activacion de fibroblastos (FAP), proteoglucano de sulfato de condroitina asociado a melanoma (MCSP), receptor de factor de crecimiento epidermico (EGFR), antigeno carcinoembrionario (CEA), CD19, CD20 o CD33. El dominio Fc de IgG formado por una primera y segunda subunidad capaces de asociarse de manera estable. Dicha molecula es util para el tratamiento de infecciones y cancer. Tambien se refiere a un polinucleotido, una celula huesped que codifica dicho anticuerpo y una composicion farmaceutica que comprende dicho anticuerpo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17150150 | 2017-01-03 | ||
| EP17164224 | 2017-03-31 | ||
| PCT/EP2018/050024 WO2018127473A1 (en) | 2017-01-03 | 2018-01-02 | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191546A1 true PE20191546A1 (es) | 2019-10-24 |
Family
ID=61024728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001290A PE20191546A1 (es) | 2017-01-03 | 2018-01-02 | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11447558B2 (es) |
| EP (1) | EP3565843A1 (es) |
| JP (1) | JP7122311B2 (es) |
| KR (1) | KR20190099527A (es) |
| CN (1) | CN110461873B (es) |
| AU (1) | AU2018206138A1 (es) |
| BR (1) | BR112019013189A2 (es) |
| CA (1) | CA3047070A1 (es) |
| CL (1) | CL2019001828A1 (es) |
| CO (1) | CO2019007046A2 (es) |
| CR (1) | CR20190309A (es) |
| IL (1) | IL267607A (es) |
| MA (1) | MA47200A (es) |
| MX (1) | MX2019007795A (es) |
| PE (1) | PE20191546A1 (es) |
| PH (1) | PH12019501440A1 (es) |
| RU (1) | RU2019123613A (es) |
| TW (1) | TW201829469A (es) |
| WO (1) | WO2018127473A1 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3489256T3 (pl) | 2014-11-14 | 2021-08-23 | F. Hoffmann-La Roche Ag | Cząsteczki wiążące antygen zawierające trimer liganda z rodziny TNF |
| EP3973980A1 (en) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| CN115594765A (zh) | 2015-10-02 | 2023-01-13 | 豪夫迈·罗氏有限公司（Ch） | 对共刺激性tnf受体特异性的双特异性抗体 |
| KR102692708B1 (ko) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| EP3601345A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| KR102364599B1 (ko) | 2017-04-04 | 2022-02-21 | 에프. 호프만-라 로슈 아게 | Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자 |
| SG11201909160WA (en) | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| AU2018253176B2 (en) | 2017-04-13 | 2023-02-02 | Agenus Inc. | Anti-CD137 antibodies and methods of use thereof |
| BR112020006443A2 (pt) | 2017-11-01 | 2020-09-29 | F. Hoffmann-La Roche Ag | anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| MX2020010638A (es) | 2018-04-11 | 2021-01-08 | Inhibrx Inc | Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados. |
| EP3774900A1 (en) | 2018-04-13 | 2021-02-17 | F. Hoffmann-La Roche AG | Her2-targeting antigen binding molecules comprising 4-1bbl |
| CN112424228B (zh) * | 2018-07-04 | 2024-08-09 | 豪夫迈·罗氏有限公司 | 新型双特异性激动性4-1bb抗原结合分子 |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| MY203902A (en) | 2018-10-01 | 2024-07-23 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212 |
| WO2020070035A1 (en) * | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules with trivalent binding to cd40 |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| TWI861039B (zh) * | 2018-12-21 | 2024-11-11 | 瑞士商赫孚孟拉羅股份公司 | 靶向腫瘤之促效cd28抗原結合分子 |
| WO2021027850A1 (en) * | 2019-08-12 | 2021-02-18 | I-Mab Biopharma Co., Ltd. | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| PE20230784A1 (es) | 2020-05-19 | 2023-05-11 | Boehringer Ingelheim Int | Moleculas de fijacion para el tratamiento de cancer |
| CR20220637A (es) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19 |
| EP4274852A4 (en) * | 2021-01-11 | 2025-02-26 | Eutilex Co., Ltd. | BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF |
| WO2022170166A1 (en) * | 2021-02-08 | 2022-08-11 | Ngm Biopharmaceuticals, Inc. | Htra1-binding agents and methods of use thereof |
| WO2022243261A1 (en) * | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
| CN117616049A (zh) * | 2021-08-24 | 2024-02-27 | 江苏恒瑞医药股份有限公司 | Fap/cd40结合分子及其医药用途 |
| CN116554324B (zh) * | 2022-01-28 | 2024-06-28 | 三优生物医药(上海)有限公司 | 一种特异性识别4-1bb的抗体、其制备方法及其用途 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN119836301A (zh) * | 2022-08-26 | 2025-04-15 | 默克专利股份公司 | 包括抗msln/cd137抗体和化疗剂的癌症治疗 |
| AU2023329054A1 (en) * | 2022-08-26 | 2025-04-03 | Merck Patent Gmbh | Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025113643A1 (en) | 2023-12-01 | 2025-06-05 | Gilead Sciences Inc. | Anti-fap-light fusion protein and use thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE4106389A1 (de) | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| EP1514934B1 (en) | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| JP2003512821A (ja) | 1999-10-04 | 2003-04-08 | メディカゴ インコーポレイテッド | 外来性遺伝子の転写調節方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP2857516B1 (en) * | 2000-04-11 | 2017-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| KR101364902B1 (ko) | 2003-11-05 | 2014-02-21 | 로슈 글리카트 아게 | 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체 |
| MXPA06006406A (es) | 2003-12-05 | 2007-03-21 | Adnexus Therapeutics Inc | Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2. |
| US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN101370827B (zh) | 2005-12-21 | 2015-10-14 | 麦克罗梅特股份公司 | 具有cea抗性的药物组合物 |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| JP5803913B2 (ja) | 2010-06-29 | 2015-11-04 | コニカミノルタ株式会社 | 超音波診断装置及びプログラム |
| MA34519B1 (fr) | 2010-08-13 | 2013-09-02 | Roche Glycart Ag | Anticorps anti-fap et procédés d'utilisation |
| BR112013024574B1 (pt) | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| EA201400709A1 (ru) | 2011-12-19 | 2016-08-31 | Синиммун Гмбх | Молекула биспецифического антитела |
| US20140242077A1 (en) * | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| CA2951604A1 (en) | 2014-08-29 | 2016-03-03 | Pablo Umana | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| PL3489256T3 (pl) | 2014-11-14 | 2021-08-23 | F. Hoffmann-La Roche Ag | Cząsteczki wiążące antygen zawierające trimer liganda z rodziny TNF |
| BR112017015136A2 (pt) | 2015-01-14 | 2018-01-30 | Compass Therapeutics Llc | polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit |
| EP3973980A1 (en) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| JP6783797B2 (ja) * | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| SMT202300026T1 (it) * | 2015-05-18 | 2023-03-17 | Pieris Pharmaceuticals Gmbh | Polipeptide di fusione anti-cancro |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| CN115594765A (zh) | 2015-10-02 | 2023-01-13 | 豪夫迈·罗氏有限公司（Ch） | 对共刺激性tnf受体特异性的双特异性抗体 |
| RU2761077C1 (ru) | 2015-10-02 | 2021-12-03 | Ф. Хоффманн-Ля Рош Аг | Антитела против cd19 человека, обладающие высокой аффинностью |
| CN108026177B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗cd19xcd3 t细胞活化性抗原结合分子 |
| CA2992900A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
| EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
| EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| EP3455254B1 (en) | 2016-05-11 | 2021-07-07 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety |
| EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
| CN110087682B (zh) | 2016-12-19 | 2023-12-15 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
| KR102692708B1 (ko) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| JP7205995B2 (ja) | 2017-03-29 | 2023-01-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子 |
| EP3601345A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| KR102364599B1 (ko) | 2017-04-04 | 2022-02-21 | 에프. 호프만-라 로슈 아게 | Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자 |
| BR112020006443A2 (pt) | 2017-11-01 | 2020-09-29 | F. Hoffmann-La Roche Ag | anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo |
| CN111246884A (zh) | 2017-11-01 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 新颖的含有tnf家族配体三聚体的抗原结合分子 |
| BR112020007630A2 (pt) | 2017-11-01 | 2020-11-17 | F. Hoffmann-La Roche Ag | anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| KR102836393B1 (ko) | 2018-03-13 | 2025-07-22 | 에프. 호프만-라 로슈 아게 | 4-1bb 작용제와 항-cd20 항체의 치료 조합 |
| EP3774900A1 (en) | 2018-04-13 | 2021-02-17 | F. Hoffmann-La Roche AG | Her2-targeting antigen binding molecules comprising 4-1bbl |
| CN112424228B (zh) | 2018-07-04 | 2024-08-09 | 豪夫迈·罗氏有限公司 | 新型双特异性激动性4-1bb抗原结合分子 |
| WO2020070035A1 (en) | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules with trivalent binding to cd40 |
| MY203902A (en) | 2018-10-01 | 2024-07-23 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212 |
| CN113677403B (zh) | 2019-04-12 | 2024-12-27 | 豪夫迈·罗氏有限公司 | 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子 |
| MX2021015888A (es) | 2019-06-26 | 2022-03-22 | Hoffmann La Roche | Fusión de un anticuerpo que se une a cea y 4-1bbl. |
| CN114929734A (zh) | 2020-01-09 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 新型含有4-1bbl三聚体的抗原结合分子 |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
-
2018
- 2018-01-02 RU RU2019123613A patent/RU2019123613A/ru not_active Application Discontinuation
- 2018-01-02 AU AU2018206138A patent/AU2018206138A1/en not_active Abandoned
- 2018-01-02 CR CR20190309A patent/CR20190309A/es unknown
- 2018-01-02 PE PE2019001290A patent/PE20191546A1/es unknown
- 2018-01-02 EP EP18701244.8A patent/EP3565843A1/en not_active Withdrawn
- 2018-01-02 KR KR1020197022782A patent/KR20190099527A/ko not_active Withdrawn
- 2018-01-02 JP JP2019536046A patent/JP7122311B2/ja active Active
- 2018-01-02 BR BR112019013189A patent/BR112019013189A2/pt not_active Application Discontinuation
- 2018-01-02 CN CN201880011647.0A patent/CN110461873B/zh not_active Expired - Fee Related
- 2018-01-02 TW TW107100076A patent/TW201829469A/zh unknown
- 2018-01-02 CA CA3047070A patent/CA3047070A1/en not_active Abandoned
- 2018-01-02 WO PCT/EP2018/050024 patent/WO2018127473A1/en not_active Ceased
- 2018-01-02 MA MA047200A patent/MA47200A/fr unknown
- 2018-01-02 MX MX2019007795A patent/MX2019007795A/es unknown
-
2019
- 2019-06-19 US US16/446,486 patent/US11447558B2/en active Active
- 2019-06-21 PH PH12019501440A patent/PH12019501440A1/en unknown
- 2019-06-24 IL IL267607A patent/IL267607A/en unknown
- 2019-06-28 CO CONC2019/0007046A patent/CO2019007046A2/es unknown
- 2019-07-01 CL CL2019001828A patent/CL2019001828A1/es unknown
-
2022
- 2022-08-15 US US17/819,867 patent/US20230045262A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7122311B2 (ja) | 2022-08-19 |
| TW201829469A (zh) | 2018-08-16 |
| CN110461873B (zh) | 2023-05-12 |
| AU2018206138A1 (en) | 2019-07-11 |
| BR112019013189A2 (pt) | 2019-12-10 |
| CO2019007046A2 (es) | 2019-07-10 |
| CR20190309A (es) | 2019-08-21 |
| CN110461873A (zh) | 2019-11-15 |
| US20230045262A1 (en) | 2023-02-09 |
| KR20190099527A (ko) | 2019-08-27 |
| CA3047070A1 (en) | 2018-07-12 |
| US11447558B2 (en) | 2022-09-20 |
| PH12019501440A1 (en) | 2020-02-10 |
| US20200190206A1 (en) | 2020-06-18 |
| EP3565843A1 (en) | 2019-11-13 |
| MA47200A (fr) | 2019-11-13 |
| RU2019123613A (ru) | 2021-02-05 |
| CL2019001828A1 (es) | 2019-10-18 |
| IL267607A (en) | 2019-08-29 |
| JP2020504622A (ja) | 2020-02-13 |
| WO2018127473A1 (en) | 2018-07-12 |
| MX2019007795A (es) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191546A1 (es) | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| IL299221A (en) | Cd3 binding antibodies | |
| CL2020003046A1 (es) | Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018) | |
| RU2018128414A (ru) | Новое psma-связывающее антитело и его применения | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| MY200988A (en) | CD3 Binding Antibodies | |
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| PE20221869A1 (es) | Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
| PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 | |
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| RU2017129236A (ru) | Мультивалентные молекулы, содержащие dr5-связывающие домены | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| AR120741A1 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| UA108466C2 (en) | Antibody antagonises c-Met | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| WO2020257789A3 (en) | Anti-tim-3 antibodies |